false
Anshul Mangal
Groundbreaking biotech entrepreneur, executive, and investor, dedicated to delivering transformative treatments to the patients who need them. Pioneered the industrialization of advanced therapeutics, including some of the earliest commercially approved cell and gene therapies, radioligand treatments, RNA-based therapies, and cutting-edge biologics. Created the leading global biologics and advanced therapy engineering consulting firm and developed the largest cell and gene therapy manufacturing footprint in the world. Deeply committed to advancing next-generation medicines, serves on multiple boards, philanthropic organizations, and patient-advocacy groups, including IQHQ, Alliance for Regenerative Medicines, and Alliance for mRNA Medicines.
-
Read: The BIOSECURE Act’s Impact May Outlive the Bill Itself The BIOSECURE Act’s Impact May Outlive the Bill Itself
-
Read: Chevron Deference: A New Era for Biotech Discover -
Read: Challenges & Opportunities in Cell and Gene Therapy Discover -
Read: US Crackdown on Chinese Clinical Trials: What’s at Stake for Biopharma? Discover -
Read: Will BIOSECURE Boost US Pharma? Discover -
Read: The Bottom Line on Chevron's Overturn Discover -
Read: Perspectives on the Future of the BIOSECURE Act Discover -
Read: Bracing for Impact of BIOSECURE Act Discover -
Read: When Should Biopharma Companies Buy, Partner or Develop Innovative Assets? Discover
Loading...
You've reach the end